Is Clinuvel Pharmaceuticals Ltd. (CUVL) a Buy, Sell, or Hold?
NASDAQ : CUVL
Clinuvel Pharmaceuticals Ltd.
$6.74 USD
$0.07 (0.97%)
- Volume
- 290
- Average Volume
- 3.49K
- Market Capitalization
- $339.88M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $9.00
- Year Low
- $5.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
Philippe Jacques Wolgen
Medical - Pharmaceuticals
Healthcare
CUVL
N/A
AU
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Azza Hamila | Head of Quality Assurance & Drug Safety |
| Dennis J. Wright | Chief Scientific Officer |
| Emilie Rodenburger | Director of Global Clinical Affairs |
| Linda Teng | Director of North American Operations |
| Philippe Jacques Wolgen | CEO, MD & Director |
| Lachlan Hay | Chief Operations Officer |
| Malcolm Bull | Head of Australian Operations & Investor Relations |
| Peter Vaughan | Chief Financial Officer |
| Claire Newstead-Sinclair | Company Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Clinuvel Pharmaceuticals Ltd. (NASDAQ:CUVL) Stock
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology ... for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Frequently Asked Questions
-
What is the current Clinuvel Pharmaceuticals Ltd. (CUVL) stock price?
-
Clinuvel Pharmaceuticals Ltd.(NASDAQ:CUVL) stock price is $6.74 in the last trading session. During the trading session, CUVL stock reached the peak price of $9 while $5.98 was the lowest point it dropped to. The percentage change in CUVL stock occurred in the recent session was 0.97% while the dollar amount for the price change in CUVL stock was $0.07.
-
CUVL's industry and sector of operation?
-
The NASDAQ listed CUVL is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
-
Who are the executives of CUVL?
-
Azza Hamila | Head of Quality Assurance & Drug Safety
Dennis J. Wright | Chief Scientific Officer
Emilie Rodenburger | Director of Global Clinical Affairs
Linda Teng | Director of North American Operations
Philippe Jacques Wolgen | CEO, MD & Director -
How many employees does CUVL have?
-
Number of CUVL employees currently stands at None. CUVL operates from 535 Bourke Street, Melbourne, VIC 3000, AU.
-
Link for CUVL official website?
-
Official Website of CUVL is: https://www.clinuvel.com
-
How do I contact CUVL?
-
CUVL could be contacted at phone #None and can also be accessed through its website. CUVL operates from 535 Bourke Street, Melbourne, VIC 3000, AU.
-
How many shares of CUVL are traded daily?
-
The average number of CUVL shares traded daily for last 3 months was 3.49K.
-
What is the market cap of CUVL currently?
-
The market value of CUVL currently stands at $339.88M with its latest stock price at $6.74